胆管癌EGFR信号通路与靶向治疗的关系  

EGFR signaling pathway and targeted therapy for cholangiocarcinoma

作　　者：杨梓琪[1] 樊利芳[1] 

机构地区：[1]武汉大学基础医学院病理教研室,湖北省武汉市430071

出　　处：《世界华人消化杂志》2013年第6期514-520,共7页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.81000987~~

摘　　要：胆管癌早期诊断困难,预后差.表皮生长因子受体(epidermal growth factor receptor,EGFR)的过表达在恶性肿瘤的演进中起重要作用.以EGFR为靶点进行靶向治疗已成为肿瘤治疗的热点,研究人员已开发出针对EGFR家族的一些抗体及抑制剂,并进行细胞学实验及临床试验,取得了初步效果.目前用于EGFR靶向性治疗肿瘤的药物主要分为两类:EGFR单克隆抗体和小分子酪氨酸激酶拮抗剂.这些EGFR靶向性治疗药物在胆管癌方面的研究,主要限于体外实验阶段,临床仅有极少量试验性报道.因此,综合阐述胆管癌EGFR信号通路、对其有效的靶向治疗方法及k-ras等基因的状况对于EGFR靶向治疗和胆管癌预后的影响,对于发展胆管癌治疗的新方向、深入胆管癌临床治疗的研究具有十分重要的意义.Cholangiocarcinoma has a poor prognosis and is difficult to detect in early stage. Overexpres- sion of epidermal growth factor receptor （EGFR） plays an important role in the evolution of malignant tumors, and EGFR-targeted therapy has become a hotspot in cancer treatment. Various monoclonal antibodies and small molecule tyrosine kinase inhibitors targeting EGFR have been developed. Currently, there have been only very few reported clinical trials that assessed the efficacy of EGFR-targeted drugs in the management of cholangiocarcinoma. A comprehensive description of the EGFR signaling pathway and EGFR-targeted treatment for cholangiocarcinoma has great significance for the treatment of this malignancy.

关 键 词：胆管癌 表皮生长因子受体信号通路 K-RAS 西妥昔 酪氨酸酶抑制剂 靶向治疗 

分 类 号：R735.8[医药卫生—肿瘤]